{
    "Trade/Device Name(s)": [
        "N Latex FLC kappa",
        "N Latex FLC lambda",
        "N Latex FLC kappa assay",
        "N Latex FLC lambda assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K193047",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031016"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFH",
        "DEH"
    ],
    "Summary Letter Date": "October 2, 2020",
    "Summary Letter Received Date": "October 5, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5550"
    ],
    "Regulation Name(s)": [
        "Immunoglobulin (light chain specific) immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Free light chains kappa",
        "Free light chains lambda"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BN Systems",
        "Atellica CH Analyzer",
        "BN II",
        "BN ProSpec Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced immunoassay",
        "Nephelometry"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens N Latex FLC kappa and lambda assays to quantitatively measure free light chains in serum and EDTA plasma for aid in diagnosis and monitoring of MM, AL, and evaluation of MGUS.",
    "Indications for Use Summary": "For quantitative determination of free light chains kappa and lambda in serum and EDTA plasma as an aid in diagnosis and monitoring of multiple myeloma (MM), diagnosis of amyloidosis (AL), and evaluation of Monoclonal Gammopathy of Undetermined Significance (MGUS) on BN Systems and Atellica CH Analyzer.",
    "fda_folder": "Immunology"
}